Holen Sie sich die Stockscreener-App
9.30
2.31%
-0.22
Schlusskurs vom Vortag:
$9.52
Offen:
$9.67
24-Stunden-Volumen:
236.40K
Relative Volume:
2.00
Marktkapitalisierung:
$134.09M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-1.8343
EPS:
-5.07
Netto-Cashflow:
$1.14M
1W Leistung:
-7.92%
1M Leistung:
-3.63%
6M Leistung:
-22.24%
1J Leistung:
-45.87%
1-Tages-Spanne:
$9.27
$9.7863
1-Wochen-Bereich:
$9.27
$10.07
52-Wochen-Spanne:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.30 | 137.29M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-01 | Bestätigt | Barrington Research | Outperform |
| 2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
| 2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Eingeleitet | Stephens | Overweight |
| 2021-07-16 | Eingeleitet | UBS | Neutral |
| 2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Eingeleitet | BWS Financial | Sell |
| 2019-09-24 | Bestätigt | Barrington Research | Outperform |
| 2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
| 2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Bestätigt | Barrington Research | Outperform |
| 2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
How Anika Therapeutics Inc. (AKP) stock reacts to Fed tighteningMarket Volume Report & Smart Money Movement Alerts - newser.com
Can Anika Therapeutics Inc. (AKP) stock deliver consistent EPS growthJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Will Anika Therapeutics Inc. (AKP) stock hit analyst forecastsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Will Anika Therapeutics Inc. stock benefit from sector rotationWeekly Investment Report & Fast Gain Stock Tips - newser.com
How Anika Therapeutics Inc. stock responds to policy changesPortfolio Performance Summary & Risk Controlled Swing Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy on weakness - newser.com
How Anika Therapeutics Inc. (AKP) stock reacts to fiscal policies2025 Earnings Impact & Technical Entry and Exit Tips - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.2025 Retail Activity & AI Driven Price Forecasts - newser.com
How strong is Anika Therapeutics Inc. stock balance sheet2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
Is Anika Therapeutics Inc. stock attractive after correctionJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flowsEarnings Performance Report & Real-Time Stock Entry Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy before new product rolloutIPO Watch & Daily Profit Maximizing Tips - newser.com
Why Anika Therapeutics Inc. (AKP) stock stays resilient2025 Market Outlook & Reliable Breakout Forecasts - newser.com
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 Volatility Report & AI Powered Trade Plan Recommendations - newser.com
Will Anika Therapeutics Inc. stock reach all time highs in 20252025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock resilient in recession scenariosPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Is Anika Therapeutics Inc. stock undervalued vs historical averages2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
6.17%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):